Stattic suppresses p‑STAT3 and induces cell death in T‑cell acute lymphoblastic leukemia
Molecular Medicine Reports · 2024
DOI: 10.3892/mmr.2024.13416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Medicine Reports, 2024. Verfasst von Chia-Ling Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Children's Medical Center, Taichung Veterans General Hospital, Taichung 407, Taiwan, R.O.C. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Apoptosis, Cyclic S-Oxides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The present study investigated the therapeutic potential of Stattic, a selective inhibitor of STAT3, in treating T‑cell acute lymphoblastic leukemia (T‑ALL). The effects of Stattic on cell viability, STAT3 phosphorylation, apoptosis and autophagy in T‑ALL cell lines, and on tumor growth in a xenograft mouse model of T‑ALL, were assessed. Methods, including the Cell Counting Kit‑8 assay for cell viability, propidium iodide/Annexin V staining for apoptosis detection, western blotting for protein expression analysis, and a xenograft mouse model for evaluating in vivo tumor growth, were employed. The results showed that Stattic effectively reduced cell viability in a dose‑dependent manner, with significant reductions observed at concentrations of 1.25 µM and above in CCRF‑CEM cells (IC50=3.188 µM) and at 2.5 µM and above in Jurkat cells (IC50=4.89 µM) after 24 h of treatment. Concurrently, Stattic significantly suppressed the expression of phosphorylated STAT3, indicating its mechanism of action as a STAT3 pathway inhibitor. Furthermore, Stattic treatment induced both apoptosis and autophagy in CCRF‑CEM and Jurkat cells, as evidenced by the respective upregulation of cleaved caspase‑3 and LC3B. In a xenograft mouse model of T‑ALL, Stattic markedly inhibited tumor growth, with the greatest effect occurring at the highest dose of 30 mg/kg. These results suggested that Stattic holds promise as a therapeutic agent in T‑ALL by modulating key pathways involved in cell survival and proliferation. In conclusion, Stattic exhibited a significant therapeutic potential for T‑ALL via a dose‑dependent reduction of cell viability, inhibiting STAT3 phosphorylation, and promoting both apoptotic and autophagic cell death; however, further studies are required before clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Medical Center, Taichung Veterans General Hospital, Taichung 407, Taiwan, R.O.C.
- Department of Physical Therapy, Hung‑Kuang University, Taichung 433, Taiwan, R.O.C.
- Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan, R.O.C.
- Department of Medical Research, Taichung Veterans General Hospital, Taichung 407, Taiwan, R.O.C.
- Department of Pathology, Tri‑Service General Hospital Penghu Branch, Magong, Penghu County 880, Taiwan, R.O.C.
Zitieren
APA
Li, C. L., Chen, H. Y., Yen, J. C., Yu, S. J., Chou, T. Y., Yeh, S. W., Chuang, H. Y., & Huang, F. L. (2024). Stattic suppresses p‑STAT3 and induces cell death in T‑cell acute lymphoblastic leukemia. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2024.13416
Vancouver
Li CL, Chen HY, Yen JC, Yu SJ, Chou TY, Yeh SW, et al. Stattic suppresses p‑STAT3 and induces cell death in T‑cell acute lymphoblastic leukemia. Molecular Medicine Reports. 2024. doi:10.3892/mmr.2024.13416
BibTeX
@article{Li2024,
author = {Li, Chia-Ling and Chen, Han-Yu and Yen, Jiin-Cherng and Yu, Sheng-Jie and Chou, Ting-Yu and Yeh, Sih-Wen and Chuang, Huai-Yu and Huang, Fang-Liang},
title = {Stattic suppresses p‑STAT3 and induces cell death in T‑cell acute lymphoblastic leukemia},
journal = {Molecular Medicine Reports},
year = {2024},
doi = {10.3892/mmr.2024.13416}
}
EUVIMED